CLAIMS

1. A compound of Formula (I):



(I)

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from C and N;

R^1, R^2, R^3, and R^4, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^6R^7$, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CONR^6R^7$, $-C(=NR^6)NR^7R^8$, $-NR^6COR^7$, $-NR^6CONR^7R^8$, $-NR^6CO_2R^7$, $-SO_2R^6$, $-NR^6SO_2NR^7R^8$, $-NR^6SO_2R^7$, and $-NR^6SO_2$aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are independently optionally substituted with at least one substituent R^9, or (R^1 and R^2), and /or (R^3 and R^4) , together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9; provided that R^1 is absent when Q is N;

R^5 is each selected from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl rings, each of which is optionally substituted with at least one substituent R^9;

R^6, R^7 and R^8, which may be the same or different, are each selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or (R^6 and R^7), and /or (R^7 and R^8) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9;

R^9 is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -alkyl-NR'R", -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", nitro, -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group are each independently optionally substituented by one, two or three substituents selected from halo, alkyl and haloalkyl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a

ring selected from heterocyclyl optionally substituted by halogen and alkyl, and heteroaryl rings optionally substituted by halogen and alkyl.

2. The compound of Claim 1, wherein Q is C.

3. The compound of Claim 1, wherein Q is N and R^1 is absent.

4. The compound of Claim 1 or 2, wherein R^1 and R^2, which may be the same or different, are each selected from hydrogen, halogen, and alkyl optionally substituted with at least one substituent R^9.

5. The compound of Claim 1 or 2, wherein each of R^1 and R^2 is hydrogen.

6. The compound of any one of Claims 1 to 5, wherein R^3 and R^4, which may be the same or different, are each selected from hydrogen, halogen, and alkyl optionally substituted with at least one substituent R^9, $-NR^6R^7$, and $-CONR^6R^7$, wherein R^6 and R^7 are each selected from hydrogen or alkyl.

7. The compound of any one of Claims 1 to 5, wherein R^3 is halogen, and alkyl optionally substituted with at least one substituent R^9, $-NR^6R^7$, and $-CONR^6R^7$ and R^4 is hydrogen, wherein R^6 and R^7 are each selected from hydrogen or alkyl.

8. The compound of any one of Claims 1 to 5, wherein R^3 is $-NR^6R^7$, and $-CONR^6R^7$ and R^4 is hydrogen, wherein R^6 and R^7 are each selected from hydrogen or alkyl.

9. The compound of any one of Claims 1 to 5, wherein R^3 and R^4 together with the ring to which they are attached, form a fused ring selected from a heterocycle or heteroaryl ring, said ring being optionally substituted with at least one substituent R^9.

10. The compound of any one of Claims 1 to 5, wherein R^3 and R^4 together with the ring to which they are attached, form a fused ring selected from naphthyridinyl, pyridooxazinyl, pyridopyrimidinyl, and purinyl, said ring being optionally substituted with oxo.

11. The compound of any one of Claims 1 to 5, wherein R^3 and R^4 together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9, which is reprented by , wherein R^1, R^2 and R^9 are defined as in Formula (I), and X is selected from -O-, -NR'- and -CR'R", wherein R' and R" are independently selected from H, haloalkyl, or alkyl.

12. The compound of any one of Claims 1 to 5, wherein R^3 and R^4 together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings



optionally substituted with at least one substituent R^9, which is reprented by ,

wherein R^1 and R^2 are defined as in Formula (I), and X is selected from -O-, -NR'- and -CR'R", wherein R' and R" are independently selected from H, haloalkyl, or alkyl.

13. The compound of any one of Claims 1 to 5, wherein R^3 and R^4 together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings,

which is reprented by  .

14. The compound of any one of Claims 1 to 13, wherein R^5 is alkyl optionally substituted with at least one substituent R^9 as defined in Formula (I) of Claim 1.

15. The compound of any one of Claims 1 to 13, wherein R^5 is methyl, ethty, propyl, isppopyl, butyl, tert-butyl, pentyl, neopentyl, hexyl, octyl, nonyl or decyl, each of which is optionally substituted with one or two or three halogen.

16. The compound of any one of Claims 1 to 13, wherein R^5 is aryl optionally substituted with at least one substituent R^9 as defined in Formula (I) of Claim 1.

17. The compound of any one of Claims 1 to 13, wherein R^5 is phenyl or naphthyl or indanyl, each of which is optionally substituted with one or two or three substituent R^9 as defined in Formula (I) of Claim 1.

18. The compound of any one of Claims 1 to 13, wherein R^5 is phenyl or naphthyl or indanyl, each of which is optionally substituted with one or two or three substituent R^9 selected from halogen, haloalkyl, alkyl, alkenyl, alkynyl, -alkyl-NR'R", -CN, -OR', -NR'R", and nitro, wherein R' and R" are independently selected from H, haloalkyl, and alkyl, or (R' and R") together with the nitrogen atom to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl.

19. The compound of any one of Claims 1 to 13, wherein R^5 is heteroaryl optionally substituted with at least one substituent R^9 as defined in Formula (I) of Claim 1.

20. The compound of any one of Claims 1 to 13, wherein R^5 is pyridinyl or pyrimidinyl, each of which is optionally substituted with one or two or three substituent R^9 as defined in Formula (I) of Claim 1.

21. The compound of any one of Claims 1 to 13, wherein R^5 is pyridinyl or pyrimidinyl, each of which is optionally substituted with one or two or three substituent R^9 selected from halogen, haloalkyl, alkyl, alkenyl, alkynyl, -alkyl-NR'R", -CN, -OR', -NR'R", and nitro, wherein R' and R" are independently selected from H, haloalkyl, and alkyl, or (R' and R") together with the nitrogen atom to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl.

22. The compound of any one of Claims 1 to 13, wherein R^5 is heterocyclyl optionally substituted with at least one substituent R^9 as defined in Formula (I) of Claim 1.

23. The compound of any one of Claims 1 to 13, wherein R^5 is tetrahydropyranyl or piperidinyl, each of which is optionally substituted with one or two or three substituent R^9 as defined in Formula (I) of Claim 1.

24. The compound of any one of Claims 1 to 13, wherein R^5 is tetrahydropyranyl or piperidinyl, each of which is optionally substituted with one or two or three substituent R^9 selected from halogen, haloalkyl, alkyl, alkenyl, alkynyl, -alkyl-NR'R", -CN, -OR', -NR'R", and nitro, wherein R' and R" are independently selected from H, haloalkyl, and alkyl, or (R' and R") together with the nitrogen atom to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl.

25. The compound of any one of Claims 1 to 13, wherein R^5 is cycloalkyl optionally substituted with at least one substituent R^9 as defined in Formula (I) of Claim 1.

26. The compound of any one of Claims 1 to 13, wherein R^5 is monocyclic or bicyclic cycloalkyl group each of which is optionally substituted with one or two or three substituent R^9 as defined in Formula (I) of Claim 1.

27. The compound of any one of Claims 1 to 13, wherein R^5 is monocyclic cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or bicyclic cycloalkyl group selected from those arranged as a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, each of which is optionally substituted with one or two or three substituent R^9 selected from halogen, haloalkyl, alkyl, alkenyl, alkynyl, -alkyl-NR'R", -CN, -OR', -NR'R", and nitro, wherein R' and R" are independently selected from H, haloalkyl, and alkyl, or (R' and R") together with the nitrogen atom to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl.

28. The compound of any one of Claims 1-27, the compound is in either of the following configurations:



Ia



Ib.

29. The compound of Claim 1, which is a compound of Formula II:



II

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

wherein:

Q is selected from C and N;

R^1, and R^2, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^6R^7$, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CONR^6R^7$, $-C(=NR^6)NR^7R^8$, $-NR^6COR^7$, $-NR^6CONR^7R^8$, $-NR^6CO_2R^7$, $-SO_2R^6$, $-NR^6SO_2NR^7R^8$, $-NR^6SO_2R^7$, and $-NR^6SO_2$aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are independently optionally substituted with at least one substituent R^9, or (R^1 and R^2) together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9; provided that R^1 is absent when Q is N;

X is selected from -O-, -NR'- and -CR'R", wherein R' and R" are independently selected from H, haloalkyl, or alkyl;

R^5 is each selected from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl rings, each of which is optionally substituted with at least one substituent R^9;

R^6, R^7 and R^8, which may be the same or different, are each selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or (R^6 and R^7), and /or (R^7 and R^8) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9;

R^9 is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -alkyl-NR'R", -CN, -OR', -NR'R", -COR', -CO_2R', -CONR'R", -C(=NR')NR"R'", nitro, -NR'COR", -NR'CONR'R", -NR'CO_2R", -SO_2R', -SO_2aryl, -NR'SO_2NR"R'", NR'SO_2R", and -NR'SO_2aryl, wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group are each independently optionally substituented by one, two or three substituents selected from halo, alkyl and haloalkyl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl, and heteroaryl rings optionally substituted by halogen and alkyl.

30. The compound of Claim 29, the compound is in either of the following configurations:



IIa



IIb.

31. The compound of Claim 1, which is a compound of Formula III:



III

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

wherein:

R^1, and R^2, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^6R^7$, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CONR^6R^7$, $-C(=NR^6)NR^7R^8$, $-NR^6COR^7$, $-NR^6CONR^7R^8$, $-NR^6CO_2R^7$, $-SO_2R^6$, $-NR^6SO_2NR^7R^8$, $-NR^6SO_2R^7$, and $-NR^6SO_2$aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are independently optionally substituted with at least one substituent R^9, or (R^1 and R^2) together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9;

R^5 is each selected from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl rings, each of which is optionally substituted with at least one substituent R^9;

R^6, R^7 and R^8, which may be the same or different, are each selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or (R^6 and R^7), and /or (R^7 and R^8) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R^9;

R^9 is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -alkyl-NR'R", -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", nitro, -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group are each independently optionally substituented by one, two or three substituents selected from halo, alkyl and haloalkyl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl

optionally substituted by halogen and alkyl, and heteroaryl rings optionally substituted by halogen and alkyl.

32. The compound of Claim 1, selected from

Compound 1.1



,

Compound 1.2



,

Compound 1.3



,

Compound 1.4



,

Compound 1.5



,

Compound 1.6



,

Compound 1.7



,

Compound 1.8



,

Compound 1.9



,

Compound 1.10



,

Compound 1.11



,

Compound 1.12



,

Compound 1.13



,

Compound 1.14



,

Compound 1.15



,

Compound 1.16



,

Compound 1.17



,

Compound 1.18



,

Compound 1.19



,

Compound 1.20



,

Compound 1.21



,

Compound 1.22



,

Compound 1.23



,

Compound 1.24



,

Compound 1.25



,

Compound 1.26



,

Compound 1.27



,

Compound 1.28



,

Compound 1.29



,

Compound 1.30



,

Compound 1.31



,

Compound 1.32



,

Compound 1.33



,

Compound 1.34



,

Compound 1.35



,

Compound 1.36



,

Compound 1.37



,

Compound 1.38



,

Compound 1.39



,

Compound 1.40



,

Compound 1.41



,

Compound 1.42



,

Compound 1.43



,

Compound 1.44



,

Compound 1.45



,

Compound 1.46



,

Compound 1.47



,

Compound 1.48



,

Compound 1.49



,

Compound 1.50



,

Compound 1.51



,

Compound 1.52



,

Compound 1.53



,

Compound 1.54



,

Compound 1.55



,

Compound 1.56



,

Compound 1.57



,

Compound 1.58



,

Compound 1.59



,

Compound 1.60



,

Compound 1.61



,

Compound 1.62



,

Compound 1.63



,

Compound 1.64



,

Compound 1.65



,

Compound 1.66



,

Compound 1.67



,

Compound 1.68



,

Compound 1.69



,

Compound 1.70



,

Compound 1.71



,

Compound 1.72



,

Compound 1.73



,

Compound 1.74



,

Compound 1.75



,

Compound 1.76



,

Compound 1.77



,

Compound 1.78



,

Compound 1.79



,

Compound 1.80



,

Compound 1.81



,

Compound 1.82



,

Compound 1.83



,

Compound 1.84



,

Compound 1.85



,

Compound 1.86



,

Compound 1.87



,

Compound 2.1



,

Compound 2.2



,

Compound 2.3



,

Compound 2.4



,

Compound 2.5



,

Compound 2.6



,

Compound 2.7



,

Compound 2.8



,

Compound 2.9



,

Compound 2.10



,

Compound 2.11



,

Compound 2.12



,

Compound 2.13



,

Compound 2.14



,

Compound 2.15



, and

Compound 2.16



,

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

33. The compound of any one of claims 1-32, having a Raf kinase and/or Raf kinase dimer inhibiting activity corresponding to a IC_{50} of 10 μM or less in a Raf enzyme assay.

34. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and as an active ingredient a therapeutically effective amount of the compound of any one of claims 1-32.

35. The use of the compound of any one of claims 1-32, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in manufacture of a medicament for treating cancer responsive to inhibition of Raf kinase and/or Raf kinase dimer.

36. A method for making a medicament for inhibiting the activity of Raf kinase and/or Raf kinase dimer, comprising including into the medicament the compound of any one of claims 1-32.

37. The use of the compound of any one of claims 1-32, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in manufacture of a medicament for treating or preventing cancer selected from the group consisting of melanomas and thyroid cancer, Barret's

adenocarcinoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, hematologic cancers, cancer of Billary Tract, Non-small -cell-lung cancer, endometrium cancer, blood cancer, large intestinal colon carcinoma, histiocytic lymphoma, and lung adenocarcinoma.